- Fecal Incontinence
|Australia IBD Microbiome (AIM) Study: protocol for a multicentre longitudinal prospective cohort study
BMJ Open. 2021 Feb 16;11(2):e042493. doi: 10.1136/bmjopen-2020-042493.
Astrid-Jane Williams 1 2, Ramesh Paramsothy 3, Nan Wu 4, Simon Ghaly 5, Steven Leach 6, Sudarshan Paramsothy 7 8, Crispin Corte 9, Claire O'Brien 10, Catherine Burke 11, Gabrielle Wark 5, Dorit Samocha-Bonet 12, Kelly Lambert 13 14, Golo Ahlenstiel 15, Valerie Wasinger 16, Shoma Dutt 17, Paul Pavli 18, Michael Grimm 4, Daniel Lemberg 19, Susan Connor 1 20, Rupert Leong 21, Georgina Hold 22
Introduction: Crohn's disease and ulcerative colitis are common chronic idiopathic inflammatory bowel diseases (IBD), which cause considerable morbidity. Although the precise mechanisms of disease remain unclear, evidence implicates a strong multidirectional interplay between diet, environmental factors, genetic determinants/immune perturbations and the gut microbiota. IBD can be brought into remission using a number of medications, which act by suppressing the immune response. However, none of the available medications address any of the underlying potential mechanisms. As we understand more about how the microbiota drives inflammation, much interest has focused on identifying microbial signals/triggers in the search for effective therapeutic targets. We describe the establishment of the Australian IBD Microbiota (AIM) Study, Australia's first longitudinal IBD bioresource, which will identify and correlate longitudinal microbial and metagenomics signals to disease activity as evaluated by validated clinical instruments, patient-reported surveys, as well as biomarkers. The AIM Study will also gather extensive demographic, clinical, lifestyle and dietary data known to influence microbial composition in order to generate a more complete understanding of the interplay between patients with IBD and their microbiota.
Methods: The AIM Study is an Australian multicentre longitudinal prospective cohort study, which will enrol 1000 participants; 500 patients with IBD and 500 healthy controls over a 5-year period. Assessment occurs at 3 monthly intervals over a 24-month period. At each assessment oral and faecal samples are self-collected along with patient-reported outcome measures, with clinical data also collected at baseline, 12 and 24 months. Intestinal tissue will be sampled whenever a colonoscopy is performed. Dietary intake, general health and psychological state will be assessed using validated self-report questionnaires. Samples will undergo metagenomic, transcriptomic, proteomic, metabolomic and culturomic analyses. Omics data will be integrated with clinical data to identify predictive biomarkers of response to therapy, disease behaviour and environmental factors in patients with IBD.
Ethics and dissemination: Ethical approval for this study has been obtained from the South Eastern Sydney Local Health District Research Ethics Committee (HREC 2019/ETH11443). Findings will be reported at national and international gastroenterology meetings and published in peer-reviewed journals.
Trial registration number: ACTRN12619000911190.